Bookmark and Share
BioAssay: AID 1430

HTS assay for inhibitors of Trypanosoma brucei hexokinase 1

Trypanosoma brucei, the digenic protozoan parasite that causes African sleeping sickness in man, annually infects ~500,000 people in sub-Saharan Africa, leading to 50,000-70,000 deaths per year. Glucose metabolism is essential for the parasite, with the pathogenic lifestage of the parasite, the bloodstream form (BSF), acquiring energy exclusively through glycolysis. ..more
_
   
 Tested Compounds
 Tested Compounds
All(220227)
 
 
Active(239)
 
 
Inactive(219990)
 
 
 Tested Substances
 Tested Substances
All(220335)
 
 
Active(239)
 
 
Inactive(220096)
 
 
AID: 1430
Data Source: University of Pittsburgh Molecular Library Screening Center (MH082340)
BioAssay Type: Primary, Primary Screening, Single Concentration Activity Observed
Depositor Category: NIH Molecular Libraries Screening Center Network
Deposit Date: 2008-11-10

Data Table ( Complete ):           Active    All
Target
BioActive Compounds: 239
Depositor Specified Assays
AIDNameTypeProbeComment
1632HTS assay for inhibitors of Trypanosoma brucei hexokinase 1: IC50 determinationsconfirmatory
2230Confirmation assay for inhibitors of Trypanosoma brucei hexokinase 1-Analogue-first seriesconfirmatory
2516G6DPH counterscreen for TbHK1 inhibitors - primary screen of DPI cherry picked compoundsother
2560Rescreen of TbHK1 primary actives - DPI cherry picked compoundsother
2579G6DPH counterscreen for TbHK1 inhibitors - Analogues seriesconfirmatory
2600Identification of Inhibitors of Trypanosoma Brucei Hexokinases - summary assaysummary1
449725IMR-90 (cell viability counter screen)confirmatory
492951Human Glck Counter Screen Assayconfirmatory
Description:
Excerpt from MH0882340 application (Dr. James Morris, Clemson University)

Trypanosoma brucei, the digenic protozoan parasite that causes African sleeping sickness in man, annually infects ~500,000 people in sub-Saharan Africa, leading to 50,000-70,000 deaths per year. Glucose metabolism is essential for the parasite, with the pathogenic lifestage of the parasite, the bloodstream form (BSF), acquiring energy exclusively through glycolysis.

Hexokinase (HK), the first enzyme in glycolysis, catalyses the transfer of the phosphoryl group of ATP to glucose yielding glucose-6-phosphate. Several lines of experimental evidence confirm that HK activity is essential to T. brucei. First, RNA interference (RNAi) of HK in BSF parasites is lethal (see below and (Albert et al., 2005)). Also, attempts to generate knockouts have been unsuccessful (below and (Albert et al., 2005)). Last, specific inhibitors of TbHK activity have been developed that are trypanocidal, albeit at high concentrations (Trinquier et al., 1995; Willson et al., 2002).

T. brucei expresses two nearly identical HKs, TbHK1 and 2, from genes found in tandem on chromosome 10. Interestingly, the polypeptides are 98% identical. TbHK1 and 2 are distinct from mammalian HKs, however, sharing only 30-33% sequence identity. The biochemical differences between TbHKs and human HK suggest that TbHKs could be therapeutic targets. Indeed, it has been suggested that the possibility of developing specific inhibitors for TbHKs is far from remote (Opperdoes and Michels, 2001), and now our ability to generate active recombinant protein makes identifying long sought-after inhibitors a possibility.

Thus, a simple "mix and read" absorption-based assay was adapted to HTS format by the University of Pittsburgh Molecular Library Screening Center (PMLSC, a part of the Molecular Library Screening Center Network (MLSCN)) and was used to screen the MLSCN compound library for inhibitors of the enzyme.
Protocol
Basic High Throughput Screening Assay protocol

The basic procedure for the TbHK1 HTS assay follows a stepwise addition of reaction mixture components as follows:

1 15 uL of a 30 uM concentration of test compound is added to appropriate wells (final compound concentration 10 uM).

2 15 uL of a glucose + ATP + MgCl2 + NAD+ + G6PDH mixture is added with final concentrations of 0.5mM, 0.35mM, 1.5mM, 3mM, and 0.006mUnits/uL, respectively.

3 15 uL of TbHK1 enzyme is added per well (final 0.5ng/uL).

4 Reaction incubates for 2 hours at room temperature.

5 5 uL EDTA is added (final 50mM).

6 Data was captured at A340 and represents the increase in NADH
in the reaction mixture.
Comment
Activity Criteria, Secondary Assay Plan, Hit and Lead Criteria

Based on the data generated in the PMLSC assay protocol review document we recommend an active criterion for the TbHK1 HTS >/= 50% inhibition.
PUBCHEM_ACTIVITY_OUTCOME

If HTS % Inhibition>=50 then PUBCHEM_ACTIVITY_SCORE=40 and PUBCHEM_ACTIVITY_OUTCOME=2

If HTS % Inhibition <50 then PUBCHEM_ACTIVITY_SCORE=0 and PUBCHEM_ACTIVITY_OUTCOME=1

Definition of Hit criteria: It is anticipated that HTS actives confirmed in IC50s will be further characterized as based on primary assay data, secondary assay data, and structural confirmation.

Rapid HTS screen >/= 50%
IC50 < 10 uM
No inhibition of secondary coupled assay
Structural confirmation by LCMS

Secondary Assay Testing Paradigm
Confirm inhibition using the primary assay format for IC50 determinations and eliminate false positives by counterscreening with the coupled reaction.
Result Definitions
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
ScoreThe BioAssay activity ranking scoreInteger
1HTS raw dataRaw HTS dataFloat
2HTS % Inhibition (10μM**)Percent inhibition of the signal readoutFloat%
3Mean max signalAverage maximum control signal readoutFloat
4Mean min signalAverage minimum control signal readoutFloat
5Assay plate Z-factorZ-factor of the assay plate as calculated using the max and min controls on the assay palteFloat
6Assay plate S:BSignal to Background ratio for the assay plateFloat
7HTS Assay DateDate the HTS assay plate was processed/runString

** Test Concentration.
Additional Information
Grant Number: MH082340

Data Table (Concise)
PageFrom: